Glaxosmithkline | Les Charges D'Exploitation



Operating Expenses Changement Date
AbbVie USD 9.61B 6.98B 2025-03
Amgen USD 6.78B 401M 2024-12
AstraZeneca USD 12.86B 2.06B 2024-12
Aurora Cannabis CAD 51.98M 31.53M 2024-12
Bausch Health Companies USD 2.19B 212M 2024-09
Bristol-Myers Squibb USD 8.23B 3.32B 2025-03
Canopy Growth CAD 98.58M 10.03M 2024-12
Corcept Therapeutics USD 156.63M 20.68M 2024-12
Drreddys Laboratories INR 64.87B 2.26B 2024-12
Eli Lilly USD 8.38B 1.53B 2024-12
GlaxoSmithKline GBP 7.42B 402M 2024-12
Glaxosmithkline GBP 7.42B 408M 2024-12
Indivior 200M 193M 2025-03
J&J USD 8.26B 10.37B 2025-03
Merck USD 9.66B 1.67B 2025-03
Novartis USD 11.28B 1.73B 2024-12
Pacira USD 162.55M 145.55M 2024-12
Perrigo USD 1.03B 13.4M 2024-12
Pfizer USD 18.17B 5.63B 2024-12
Prestige Brands USD 198.36M 1.09M 2024-12
Roche Holding CHF 11.43B 1.48B 2024-12
Sanofi EUR 8.32B 1.55B 2025-03
Supernus Pharmaceuticals USD 152.75M 17.91M 2024-12
Takeda JPY 1.08T 85.39B 2024-12
Teva Pharmaceutical Industries USD 3.77B 609M 2024-12
Zoetis USD 1.59B 71M 2024-12



Glaxosmithkline Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.